Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Accumulated Depreciation & Amortization (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $22.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 37.67% to $22.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.1 million through Dec 2025, up 37.67% year-over-year, with the annual reading at $22.1 million for FY2025, 37.67% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $22.1 million at Kymera Therapeutics, down from $22.4 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $22.4 million in Q3 2025, with the low at $2.6 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $10.4 million, with a median of $9.1 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 95.34% in 2021, then surged 35.23% in 2024.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $3.9 million in 2021, then soared by 76.02% to $6.9 million in 2022, then skyrocketed by 51.46% to $10.4 million in 2023, then soared by 53.96% to $16.1 million in 2024, then skyrocketed by 37.67% to $22.1 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $22.1 million, $22.4 million, and $20.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.